Lipid profile: causal relationship on cognitive performance in multiple sclerosis?

Mol Biol Rep. 2020 Dec;47(12):9667-9676. doi: 10.1007/s11033-020-06011-3. Epub 2020 Dec 1.

Abstract

Although cognitive impairment (CI) is classically associated with aging, it has been proposed that neurological pathologies may increase the risk to suffer CI. Despite the evidence of an elevated prevalence of CI in patients with multiple sclerosis (MS), it is not considered among standard clinical evaluations, due the lack of specialists and time required. The aim of this study was to evaluate if lipid profile is associated with cognitive performance in persons with MS. Twenty patients with MS were evaluated. Montreal Cognitive Assessment (MoCA) was employed to determine cognitive performance. CI was observed in 85% of patients, with memory recall and language as the most affected domains. Despite biomarkers were mostly found within reference values, several correlations were observed. MoCA total score was correlated with cholesterol (r = - 0.468, p = 0.037) and LDL (r = - 0.453, p = 0.045). Visuospatial domain was correlated with LDL (r = - 0.493, p = 0.027). Attention domain correlated with triglycerides (r = - 0.455, p = 0.044) and cholesterol (r = - 0.549, p = 0.012). When the person reaches borderline levels of triglycerides, LDL and cholesterol a decrease in cognitive performance can be observed. The mechanism underlying this association has not been established still, it has been proposed that it could be linked with neuroinflammation, alterations in synapses and in the metabolism of amyloid-β protein. This study settles the potential importance that lipid profile could have on cognitive performance in MS. Further studies are needed to establish optimal levels and implication of lipid profile in the diagnosis and monitoring of cognitive performance in Mexican people with MS.

Keywords: Biomarker; Cognitive impairment; Lipid profile; Multiple sclerosis.

MeSH terms

  • Adult
  • Biomarkers / blood
  • Cholesterol, HDL / blood*
  • Cholesterol, LDL / blood*
  • Cholesterol, VLDL / blood*
  • Cognition / physiology
  • Cognitive Dysfunction / blood*
  • Cognitive Dysfunction / drug therapy
  • Cognitive Dysfunction / immunology
  • Cognitive Dysfunction / physiopathology
  • Female
  • Glatiramer Acetate / therapeutic use
  • Humans
  • Immunologic Factors / therapeutic use
  • Interferons / therapeutic use
  • Lipidomics / methods
  • Male
  • Middle Aged
  • Multiple Sclerosis / blood*
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / immunology
  • Multiple Sclerosis / physiopathology
  • Triglycerides / blood*

Substances

  • Biomarkers
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Cholesterol, VLDL
  • Immunologic Factors
  • Triglycerides
  • Glatiramer Acetate
  • Interferons